Pharmachim S.A. announces an exclusive commercialization agreement with Samsung Bioepis for a portfolio of products in Greece
Athens, September 21, 2026 – Pharmachim S.A. today announced a strategic, exclusive agreement with Samsung Bioepis NL B.V. in Greece. Under the terms of the agreement, Pharmachim S.A. will obtain exclusive commercial rights to a wide portfolio of products in Greece and will lead local market access, medical, and commercial activities, while Samsung Bioepis will maintain full development, manufacturing, and regulatory responsibilities.
Each product in the portfolio has received marketing authorization in the European Union as a biosimilar to its respective reference medicine. The portfolio spans multiple therapeutic areas, including ophthalmology, hematology, orthopedics, internal medicine, nephrology, endocrinology, and oncology.
Mr. Michael Tsatsaronis, CEO of Pharmachim S.A., stated:
"We are very pleased to announce our partnership with Samsung Bioepis, a company that shares our deep commitment to addressing significant unmet medical needs. Biosimilars play a critical role in improving patient access to advanced biological therapies while easing the financial burden on healthcare systems. This agreement allows us to leverage our extensive infrastructure and expertise in specialty medicines to ensure that eligible patients in Greece gain timely access to these biologic therapies."
With this agreement, Pharmachim and Samsung Bioepis reinforce their shared commitment to delivering more treatment options that can help reduce spending pressures on the healthcare system and expand patient access to high-quality biologic medicines in Greece.
About Pharmachim S.A.
Pharmachim S.A. is a leading pharmaceutical company based in Greece, specializing in the commercialization of innovative therapies and orphan drugs. By partnering with leading global biopharmaceutical organizations, Pharmachim utilizes its robust expertise in regulatory affairs, market access, and commercial execution to improve patient access to advanced specialty medicines across Greece and Cyprus. Pharmachim is a member of the Prime Group of companies.
About Samsung Bioepis
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Bioepis Holdings, Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. Its European operations are conducted through Samsung Bioepis NL B.V., headquartered at Olof Palmestraat 10, 2616 LR Delft, Netherlands.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" regarding, among other things, the commercialization of the product portfolio in Greece pursuant to the agreement between Pharmachim S.A. and Samsung Bioepis, and the anticipated benefits of that agreement for patients and healthcare systems. Forward-looking statements may be identified by words such as "will," "expected," "aim," "plan," and words of similar meaning, and are based on current beliefs and expectations. These statements are subject to significant risks and uncertainties, including those relating to regulatory processes, market access, reimbursement, and commercialization, and actual results may differ materially from those expressed or implied. Neither Pharmachim S.A. nor Samsung Bioepis undertakes any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media Contact
Pharmachim S.A.
Phone: (+30) 210-5775475
Email: info@pharmachim.gr
www.pharmachim.gr